F/m Emerald Life Sciences Innovation ETF LFSC
Set alert
43.27 USD -0.31 -0.70%
At close · Nov 2
43.27 0.00 0.00%
After hours · Nov 2, 4:00 PM ET
43.13 Day range 44.00
31.02 52-week range 48.78
- YTD
- +18.17%
- 1 year
- +31.65%
- Open
- 44.00
- Prev close
- 43.58
- Mkt cap
- 121.00M
- Vol
- 5.79K
- Avg vol
- 3.42K
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 43.13
- High
- 44.00
- Forward P/E
- 0.00
- Beta
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 25.58
- 200-d avg
- 25.58
2Y chart
Signals (78)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 2026 | 4 days ago |
| SMA: Bullish | Oct 29, 2026 | 5 days ago |
| MACD: Buy Signal | Oct 21, 2026 | 1 week ago |
| SMA: Bullish | Oct 19, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 16, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 16, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 14, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 7, 2026 | 3 weeks ago |
| SMA: Bearish | Aug 28, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 20, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 19, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 11, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 10, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 13, 2026 | 3 months ago |
| RSI: Overbought | Jun 22, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 11, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 2, 2026 | 5 months ago |
| MACD: Buy Signal | May 27, 2026 | 5 months ago |
| MACD: Sell Signal | May 8, 2026 | 5 months ago |
| MACD: Buy Signal | May 4, 2026 | 6 months ago |
Newest 20 of 78.
Key statistics
- Market cap
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- Price / sales
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- 50-day average
- 25.58
- 200-day average
- 25.58
Next earnings
Consensus EPS estimate 0.00.
News
- Spyre Therapeutics Breaks Higher On Positive Data From Ulcerative Colitis Drug
- Cogent Biosciences Stock Climbs After FDA Accepts Key Drug Application
- FDA Approves Guardant Health's Blood Test To Guide Treatment For Advanced Colorectal Cancer
- Travere Stock Slips After FDA Delays Review Of Key Kidney Drug
- This New ETF Doesn't Wait For Stability — It Profits From Disruption
Your note
Sign in to keep a note on LFSC — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Financial Investors Tr-Emerald Growth Fund | 92.29% | 2,000,000 | 47.48M | Oct 30, 2024 |